Optimer Pharmaceuticals
A pharmaceutical company committed to advancing anti-infective therapies focused on gastrointestinal infections
General Information
Get notified when Optimer Pharmaceuticals moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Optimer Pharmaceuticals
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
Biotechnology
About Optimer Pharmaceuticals
Taxonomy: pharmaceutical company, biopharmaceutical, anti-infective therapies, gastrointestinal infections, drug discovery, commercialization, fidaxomicin, Pruvel, prulifloxacin, late-stage product candidates, CEM-101, OPT-822, OPT-821, combination therapy, OPT-88
Funding Rounds & Investors (3)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Series D | •••••• | 8 |
|
14 Dec 2005 |
| Series C | •••••• | 1 | •••• •••• | 02 Mar 2005 |
| Series B | •••••• | 1 |
|
24 Sep 2001 |
Optimer Pharmaceuticals Alternatives & Competitors
A dermatology-focused pharmaceutical pioneer with innovative hair growth solutions and advanced topi...
Affirma Biotech develops new products to overcome the challenge of Multi Drug Resistant and Chronic...
Developing groundbreaking anti-infective products through proprietary DNA replication technology and...
FAQ About Optimer Pharmaceuticals
Don't just browse. Track.
Signal Tracker monitors Optimer Pharmaceuticals and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.
